Claims for Patent: 7,364,736
✉ Email this page to a colleague
Summary for Patent: 7,364,736
| Title: | Antibodies to OPGL |
| Abstract: | Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described. |
| Inventor(s): | Boyle; William J. (Thousand Oaks, CA), Martin; Francis H. (Newbury Park, CA), Corvalan; Jose R. (Foster City, CA), Davis; C. Geoffrey (Burlingame, CA) |
| Assignee: | Amgen Inc. (Thousand Oaks, CA) Amgen Fremont Inc. (Fremont, CA) |
| Application Number: | 10/180,648 |
| Patent Claims: | 1. An isolated antibody comprising: a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 2; and b) a light chain comprising the amino acid sequence of SEQ ID NO: 4.
2. An isolated antibody consisting of: a) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2; and b) a light chain consisting of the amino acid sequence of SEQ ID NO: 4. 3. An isolated antibody comprising: a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 13; and b) a light chain comprising the amino acid sequence of SEQ ID NO: 14. 4. The antibody of claim 3, wherein the heavy chain and the light chain are connected by a flexible linker to form a single-chain antibody. 5. The antibody of claim 4, which is a single-chain Fv antibody. 6. The antibody of claim 3, which is a Fab antibody. 7. The antibody of claim 3, which is a Fab' antibody. 8. The antibody of claim 3, which is a F(ab').sub.2 antibody. 9. The antibody of claim 3, which is fully human. 10. The antibody of claim 3, wherein the antibody inhibits binding of a human osteoprotegerin ligand (OPGL) to an osteoclast differentiation and activation receptor (ODAR). 11. An isolated antibody comprising: a) a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13; and b) a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14. 12. The antibody of claim 11, wherein the heavy chain and the light chain are connected by a flexible linker to form a single-chain antibody. 13. The antibody of claim 12, which is a single-chain Fv antibody. 14. The antibody of claim 11, which is a Fab antibody. 15. The antibody of claim 11, which is a Fab' antibody. 16. The antibody of claim 11, which is a F(ab').sub.2 antibody. 17. The antibody of claim 11, which is fully human. 18. The antibody of claim 11, wherein the antibody inhibits binding of a human osteoprotegerin ligand (OPGL) to an osteoclast differentiation and activation receptor (ODAR). 19. A pharmaceutical composition comprising the antibody of any one of claims 1, 2, 3, and 11. 20. The pharmaceutical composition of claim 19, wherein the composition comprises an acetate buffer. 21. The pharmaceutical composition of claim 19, wherein the composition comprises polysorbate. 22. The pharmaceutical composition of claim 19, wherein the composition comprises sorbitol. 23. The pharmaceutical composition of claim 19, wherein the composition comprises acetate and sorbitol. 24. The pharmaceutical composition of claim 19, wherein the composition is contained in a prefilled syringe. 25. The pharmaceutical composition of claim 19, wherein the composition is in unit dose form. |
Details for Patent 7,364,736
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | PROLIA | denosumab | Injection | 125320 | June 01, 2010 | 7,364,736 | 2021-06-26 |
| Amgen Inc. | XGEVA | denosumab | Injection | 125320 | November 18, 2010 | 7,364,736 | 2021-06-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Showing 1 to 2 of 2 entries
International Patent Family for US Patent 7,364,736
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200400521 | ⤷ Try for Free |
| United States of America | 8409578 | ⤷ Try for Free |
| United States of America | 8058418 | ⤷ Try for Free |
| World Intellectual Property Organization (WIPO) | 03002713 | ⤷ Try for Free |
| Yugoslavia | 103003 | ⤷ Try for Free |
| >Country | >Patent Number | >Estimated Expiration |
Showing 1 to 5 of 5 entries
